Putting the "M" back in maternal-fetal medicine: A 5-year report card on a collaborative effort to address maternal morbidity and mortality in the United States
AuthorD'Alton, Mary E
Friedman, Alexander M
Bernstein, Peter S
Brown, Haywood L
Callaghan, William M
Clark, Steven L
Grobman, William A
Kilpatrick, Sarah J
O'Keeffe, Daniel F
Montgomery, Douglas M
Srinivas, Sindhu K
Wendel, George D
Wenstrom, Katharine D
Foley, Michael R
AffiliationUniv Arizona, Coll Med
Keywordsadvanced cardiac life support
amniotic fluid embolism bundles
intensive care unit
levels of maternal care
national surveillance program
MetadataShow full item record
CitationD’Alton, M. E., Friedman, A. M., Bernstein, P. S., Brown, H. L., Callaghan, W. M., Clark, S. L., ... & Srinivas, S. K. (2019). Putting the “M” back in maternal-fetal medicine: A 5-year report card on a collaborative effort to address maternal morbidity and mortality in the United States. American journal of obstetrics and gynecology.
Rights© 2019 Elsevier Inc. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractThe Centers for Disease Control and Prevention have demonstrated continuous increased risk for maternal mortality and severe morbidity with racial disparities among non-Hispanic black women an important contributing factor. More than 50,000 women experienced severe maternal morbidity in 2014, with a mortality rate of 18.0 per 100,000, higher than in many other developed countries. In 2012, the first "Putting the 'M' back in Maternal-Fetal Medicine" session was held at the Society for Maternal-Fetal Medicine's (SMFM) Annual Meeting. With the realization that rising risk for severe maternal morbidity and mortality required action, the "M in MFM" meeting identified the following urgent needs: (i) to enhance education and training in maternal care for maternal-fetal medicine (MFM) fellows; (ii) to improve the medical care and management of pregnant women across the country; and (iii) to address critical research gaps in maternal medicine. Since that first meeting, a broad collaborative effort has made a number of major steps forward, including the proliferation of maternal mortality review committees, advances in research, increasing educational focus on maternal critical care, and development of comprehensive clinical strategies to reduce maternal risk. Five years later, the 2017 M in MFM meeting served as a "report card" looking back at progress made but also looking forward to what needs to be done over the next 5 years, given that too many mothers still experience preventable harm and adverse outcomes.
Note12 month embargo; published online: 5 March 2019
VersionFinal accepted manuscript
SponsorsACOG II's Safe Motherhood Initiative from Merck for Mothers
Showing items related by title, author, creator and subject.
The effect of maternal blood phenylalanine level on mouse maternal phenylketonuria offspringLei, David K. Y.; Chung, Sangbun (The University of Arizona., 1999)Maternal phenylketonuria is a disease process caused by the adverse effects of high maternal blood phenylalanine (PHE) on the fetus. Unless treated, maternal PKU results in teratogenic effects on the fetus that can lead to mental retardation, microcephaly, intrauterine growth retardation, congenital cardiovascular defects, low birth weight, spontaneous abortion and fetal death. Although PKU has been recognized as a major challenge for many years, surprisingly little is known about the pathophysiologic mechanism(s) of PHE toward the fetus. To more thoroughly investigate the pathogenesis of this heritable disease and to explore potential therapeutic actions, the genetic mouse model Pahenu2 was used. The overall goals of this project were to use the Pah enu2 mouse to examine the effect of maternal blood PHE level on: (1) The pregnancy outcome of maternal PKU offspring as measured by the incidence of spontaneous abortion and certain key measures of development at birth (i.e., head circumference, weight, and crown-rump length of offspring); and (2) The fetal nutritional status of maternal PKU offspring as assessed by the levels of PHE, tyrosine (TYR), and other essential amino acids (EAA) at birth. In this study, we clearly observed that elevated maternal blood PHE levels, whether they were caused by the maternal diet or maternal genotype, were responsible for the fetal abnormalities in maternal PKU. With regard to fetal developmental outcomes, significant reductions in birth weight, crown-rump length, and head circumference were seen in offspring gestated under high maternal blood PHE conditions. The incidence of fetal loss was significantly different between treatment and control groups. Reductions in the levels of alanine, glutamine, and glutamic acid were observed in fetal blood among offspring born to mutant mothers with high blood PHE levels. None of the branched chain amino acids were reduced in maternal PKU offspring. These findings strongly suggest that there are important maternal genotype and dietary components but no fetal genotype component to this maternal PKU model. Given that these maternal factors also appear to be the most important components of human maternal PKU, this model seems certain to provide a valid animal model to overcome the difficulties of human studies.
REDUCING KENYA’S MATERNAL MORTALITY RATE: COMPARING MATERNAL MORTALITY DUE TO PRE-ECLAMPSIA IN KENYA AND THE U.S.Weinstein, Randi; BAHL, PAULLUVI (The University of Arizona., 2016)Previous studies show differences in maternal mortality rates (MMRs) between Kenya and the United States; for every American that dies from pre-eclampsia, 44 Kenyans die1. This literature review examines physiology, diagnosis, and management of pre-eclampsia, and external variables affecting these MMRs. A case study of a public hospital in Kenya is presented alongside healthcare worker interviews. External variables affecting patient care include clinical deficiencies and cultural factors. Clinical deficiencies include poor patient education on pre-natal care, insufficient physician education on proper detection of pre-eclampsia and management with magnesium sulfate. Cultural factors include women’s avoidance of pre-natal care, delivery with unskilled attendants outside of hospitals, and government corruption, which limits funding, staffing, and supplies. This thesis culminates in recommendations to alleviate these disparities and reduce Kenya’s MMR and a public education poster to be displayed in Kenya. Kenya’s high MMR can be reduced with better patient and physician education concerning merits of pre-natal care and hospital deliveries, symptoms of pre-eclampsia, management with magnesium sulfate, and adequate funding.